Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013
Diagnostic and prognostic value of C-reactive protein in community-acquired pneumonia hospitalized patients Source: Eur Respir J 2004; 24: Suppl. 48, 188s Year: 2004
Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP) Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment Year: 2013
Individual monitoring of procalcitonin and C-reactive protein levels as a criterion for cancel of antibiotic therapy in patients with severe community-acquired pneumonia Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013
Predictive factors for true bacteremia and clinical utility of blood cultures as a prognostic tool in patients with community-onset pneumonia Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016
Usefulness of shock index predictive value in mortality assessment in community acquired pneumonia Source: Annual Congress 2013 –Manifestations, scores and prognosis of community-acquired pneumonia Year: 2013
Prognostic value of plasma D-dimer level in adults with community-acquired pneumonia – A prospective study Source: International Congress 2015 – CAP: prognostic factors in frail patients Year: 2015
Role of procalcitonin in predicting severity and in-hospital mortality in patients with community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016
Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia Source: Eur Respir J 2008; 31: 356-362 Year: 2008
Prognosis value of initial C-reactive protein (CRP) assay in patients with community acquired pneumonia Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention Year: 2008
Usefulness of procalcitonin as a predictor for bacteremia and prognosis in severe sepsis Source: International Congress 2016 – Infections, sepsis, and pulmonary embolism Year: 2016
Prognostic power of biomarkers to predict in-hospital and postdischarge mortality in community acquired pneumonia Source: Annual Congress 2013 –A modern approach to lung diseases: from bronchi to pleura Year: 2013
Usefulness of C-reactive protein and procalcitonin levels in pulmonary tuberculosis Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014
The role of procalcitonin in predicting severity and clinical course of aspiration pneumonia Source: International Congress 2015 – CAP: prognostic factors in frail patients Year: 2015
Role of procalcitonin (PCT) as a marker of severity of community acquired bacterial pneumonia (CABP) compared to PSI, CRB65 abd CURB65 Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013
YKL-40 and CCL18 predict mortality in patients hospitalised with community-acquired pneumonia; an observational analysis Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016
Diagnostic and prognostic utility of procalcitonin (PCT) measurements in patients with hospitalized community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009
Inflammatory markers and community acquired pneumonia (CAP): Prognosis analisis and predictive capacity in the short term Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013
Comparison of the prognostic value of different severity scales in community- acquired pneumonia Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014
Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia Source: Eur Respir J 2008; 32: 726-732 Year: 2008